At Oncova Biosciences, we are pioneering a new frontier in oncology drug discovery—where artificial intelligence meets molecular science. Oncova leverages in silico drug development to rapidly identify, model, and optimize therapies for novel and previously "undruggable" cancer targets.
Insilico Medicine (tm) AI-powered discovery platform simulates molecular interactions in silico, dramatically accelerating the timeline from target identification to candidate selection. This approach allows us to uncover hidden cancer initiators and engineer precisely tuned compounds tailored to the molecular signatures of the most aggressive and treatment-resistant tumors.
From digital molecule to clinical candidate, every innovation at Oncova is rooted in the belief that data-driven insight and computational precision can unlock cures once thought impossible. We are not just discovering new cancer drugs—we are rewriting the way they are found.
Oncova Biosciences: Turning computation into cure.
Oncova-Bioinfo
Propriatary data base platform for drug target discovery
Oncova-GPT
Propriatary Chat-GPT based platform for drug Hits and Hit Leads
Meet Our Experts
The Minds Behind Oncova Biosciences
Rudolph E Willis MD
President / CEO
Scott M Kahn PhD
Scientific Advisor
Doctor Willis is a founding member of OncoStem Biotherapeutics. He is a Theoretical Biologist with over 30 years' experience in all aspects of cancer therapy and research. He is the author of the foundational theoretical biology work and the designer of the Bioinformatic Database that serves as the basis for the development of a whole new class of targeted anti-cancer drugs.
Doctor Willis earned a combined biology and chemistry B.A. degree with honors at Northwestern University. He earned his M.D. degree at Washington University School of Medicine in St. Louis. He subsequently completed a fellowship at the National Cancer Institute at NIH, where he was a Research Associate in the Laboratory of Tumor Cell Biology.
He has participated in innumerable oncology clinical trials, and is the author of several scientific and clinical papers in oncology and molecular biology.
He is a member of the American Society of Clinical Oncology, American Society for Cell Biology, and a member of the NIH Alumni Association.
He is an adjunct Assistant Professor of Medicine at Drexel University College of Medicine in Philadelphia.
Doctor Kahn brings over 30 years of experience executing and directing top-level projects in academia and industry. Doctor Kahn combines a deep understanding of oncology, personalized medicine, translational research, biomarkers, and biomedical research with a high technical acumen and an acute mind for business development. He has directed projects alongside global thought leaders, worldwide industry and academic research groups, and cross-functional teams.
Doctor Kahn's many peer-reviewed research publications include seminal contributions to cancer biology and cancer theory. He has discovered oncogenes, functionally characterized signaling pathways, worked on associations between biomarkers and clinical therapy, and provided the first evidence leading to the theory of "Oncogene Addiction", a widely accepted theory for targeted drug therapy. Doctor Kahn has also conceived of, invented, and validated innovative, state of the art and cutting-edge biomarker platforms and functional assays.
Doctor Kahn has been a member of the Herbert Irving Comprehensive Cancer Center at Columbia University.
He completed his postdoctoral studies in the Herbert Irving Comprehensive Cancer Center at Columbia University, received his Ph.D. degree in Biochemistry and Molecular Biology from SUNY at Stoney Brook, and his B.A. degree with double majors in chemistry and biochemistry from Brandeis University.
About Oncova Biosciences
Pioneering Cancer Drug Development
Our Vision
Oncova Biosciences is an emerging, virtual Biotech cancer drug development company utilizing AI and in silico methodology to produce cancer drugs targeting novel previously resistant mutated genes that intiate and maintain cancer.
Our Approach
At Oncova Biosciences, we combine cutting-edge AI technology with in silico methodology to address critical challenges in cancer drug development. We believe in pushing boundaries, exploring new frontiers, and delivering impactful solutions that have the power to revolutionize cancer treatment.
Our Work
Current Initiatives
Targeted Therapies
Developing innovative targeted therapies to address previously resistant mutated genes and improve patient outcomes.
Precision Diagnostics
Enhancing precision diagnostics for early and accurate detection of cancer mutations, leading to better treatment outcomes.
Personalized Treatments
Advancing personalized treatments to tailor therapies based on individual genetic profiles for more effective cancer care.
Novel Gene Targeting
Researching and developing novel gene targeting technology with the potential to revolutionize cancer drug development.
Testimonials
